全文获取类型
收费全文 | 286317篇 |
免费 | 18966篇 |
国内免费 | 1128篇 |
专业分类
耳鼻咽喉 | 3009篇 |
儿科学 | 7373篇 |
妇产科学 | 5378篇 |
基础医学 | 36111篇 |
口腔科学 | 5221篇 |
临床医学 | 29764篇 |
内科学 | 59285篇 |
皮肤病学 | 3978篇 |
神经病学 | 28031篇 |
特种医学 | 12072篇 |
外国民族医学 | 13篇 |
外科学 | 45462篇 |
综合类 | 3262篇 |
现状与发展 | 1篇 |
一般理论 | 230篇 |
预防医学 | 21798篇 |
眼科学 | 6629篇 |
药学 | 19166篇 |
2篇 | |
中国医学 | 370篇 |
肿瘤学 | 19256篇 |
出版年
2023年 | 1612篇 |
2022年 | 2598篇 |
2021年 | 6322篇 |
2020年 | 3608篇 |
2019年 | 5998篇 |
2018年 | 7183篇 |
2017年 | 5277篇 |
2016年 | 5757篇 |
2015年 | 6830篇 |
2014年 | 9940篇 |
2013年 | 13476篇 |
2012年 | 20632篇 |
2011年 | 21456篇 |
2010年 | 11966篇 |
2009年 | 10980篇 |
2008年 | 18906篇 |
2007年 | 19917篇 |
2006年 | 19379篇 |
2005年 | 19124篇 |
2004年 | 17948篇 |
2003年 | 16525篇 |
2002年 | 15790篇 |
2001年 | 2778篇 |
2000年 | 2247篇 |
1999年 | 2806篇 |
1998年 | 3370篇 |
1997年 | 2673篇 |
1996年 | 2377篇 |
1995年 | 2252篇 |
1994年 | 1931篇 |
1993年 | 1873篇 |
1992年 | 1511篇 |
1991年 | 1401篇 |
1990年 | 1280篇 |
1989年 | 1205篇 |
1988年 | 1095篇 |
1987年 | 985篇 |
1986年 | 1017篇 |
1985年 | 1099篇 |
1984年 | 1269篇 |
1983年 | 1081篇 |
1982年 | 1282篇 |
1981年 | 1189篇 |
1980年 | 1038篇 |
1979年 | 702篇 |
1978年 | 744篇 |
1977年 | 629篇 |
1976年 | 600篇 |
1975年 | 490篇 |
1974年 | 519篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
N. Cody Schaal Raushan A. Salaam Michael Stevens Alex Stubner 《Journal of occupational and environmental hygiene》2019,16(5):329-335
The purpose of this investigation was to characterize noise levels in spaces designated as “effective quiet” areas on a U.S. Navy aircraft carrier. Noise dosimetry samples were collected in 15 designated spaces, representing 15 noise measurements, while at-sea during airwing carrier qualifications. Equivalent sound level (Leq) measurements were collected during flight operations (Leq (flt ops)), non-flight operations (Leq (non-flt ops)), and over 24-hr periods (Leq (24-hr)). These data were compared to the 70 dBA American Conference of Governmental Industrial Hygienists (ACGIH®) Threshold Limit Value (TLV®) for “effective quiet” areas intended for temporary threshold shift recovery when personnel live and work in a potentially noise hazardous environment for periods greater than 24?hr. The monitored areas were selected based on personnel occupancy/use during off-duty time periods. Areas were classified by either (1) leisure areas that included mess (eating areas), gyms, lounges, an internet cafe, and the fantail social area or (2) berthing (sleeping) areas. The Leq measurements in decibels “A” weighted (dBA) were compared to determine significant differences between Leq (flt ops), Leq (non-flt ops), and Leq (24-hr) and were compared between leisure area and berthing area. Measured noise levels according to time period ranged as follows: (1) Leq (24-hr): 70.8–105.4 dBA; (2) Leq (flt ops): 70–101.2 dBA; and (3) Leq (non-flt ops): 39.4–104.6 dBA. All area measurements over the 24-hr period and during flight operations and 46.7% of the areas during the non-flight operation time period exceeded the “effective quiet” 70 dBA ACGIH TLV. Mean Leqs were 15 dBA higher during flight operations compared to non-flight operations in “effective quiet” areas (p?=?0.001). The Leqs in leisure areas were significantly higher than berthing areas by approximately 21 dBA during non-flight operation periods (p?=?0.001). Results suggest noise levels in “effective quiet” areas frequented by aircraft carrier personnel during off-duty hours when at-sea may inhibit auditory recovery from occupational noise exposures that occur on-duty. 相似文献
2.
This article describes a case of anaphylaxis secondary to chlorhexidine during urethral catheterisation. Despite little evidence for the use of antiseptic lubricants in preventing catheter-associated urinary tract infections, the distribution and use of such products continues to be widespread. Chlorhexidine-free lubricating gel is widely available and should be used for urological procedures wherever possible. 相似文献
3.
4.
5.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献
6.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
7.
8.
9.
Gupta Archana A. Mammo Danny A. Page Michael A. 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2020,258(1):167-173
Graefe's Archive for Clinical and Experimental Ophthalmology - To evaluate the long-term safety and efficacy of intrastromal bevacizumab for treatment of deep corneal neovascularization in... 相似文献
10.